Evidence map›Paper›PMID 30655947›Full record

ArticleACS medicinal chemistry letters2019

Reducing Limitation in Probe Design: The Development of a Diazirine-Compatible Suzuki-Miyaura Cross Coupling Reaction.

Naoko Ichiishi, Keith P Moore, Anne Mai Wassermann, Scott E Wolkenberg, Shane W Krska

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Advancement in Organic Synthesis through High Throughput Experimentation.Chemistry methods : new approaches to solving problems in chemistry · 2021
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Naoko IchiishiMerck & Co., Inc., Discovery Chemistry, HTE and Lead Discovery Capabilities, Kenilworth, New Jersey 07033, United States.
Keith P MooreMerck & Co., Inc., Discovery Chemistry, Chemical Biology, West Point, Pennsylvania 19486, United States.
Anne Mai WassermannMerck & Co., Inc., Discovery Chemistry, Chemistry Informatics, Boston, Massachusetts 02115, United States.
Scott E WolkenbergMerck & Co., Inc., Discovery Chemistry, Chemical Biology, West Point, Pennsylvania 19486, United States.
Shane W KrskaMerck & Co., Inc., Discovery Chemistry, HTE and Lead Discovery Capabilities, Kenilworth, New Jersey 07033, United States.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USUnited States Military Academy · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Access to high quality photoaffinity probe molecules is often constrained by synthetic limitations related to diazirine installation. A survey of recently published photoaffinity probe syntheses identified the Suzuki-Miyaura (S-M) coupling reaction, ubiquitous in drug discovery, as being underutilized to incorporate diazirines. To test whether advances in modern cross-coupling catalysis might enable efficient S-M couplings tolerant of the diazirine moiety, a fragment-based screening approach was employed. A model S-M coupling reaction was screened under various conditions in the presence of an aromatic diazirine fragment. This screen identified reaction conditions that gave good yields of S-M coupling product while minimally perturbing the diazirine reporter fragment. These conditions were found to be highly scalable and exhibited broad scope when applied to a chemistry informer library of 24 pharmaceutically relevant aryl boron pinacol esters. Furthermore, these conditions were used to synthesize a known diazirine-containing probe molecule with improved synthetic efficiency.

Identifiers

PMID30655947
PMCPMC6331167
OpenAlexW2903565727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.